Global Cardioselective Beta Blockers Market, By Indication (Angina, Hypertension, Heart Failure, Arrhythmias, Others), Target (Beta-1 Receptors, Beta-2 Receptors, Others), Drugs (Betaxolol, Acebutolol, Esmolol, Atenolol, Others), Route of Administration (Oral, parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cardioselective Beta Blockers Market Analysis and Size
The global cardioselective beta blockers market is expected to witness huge growth in the forecast period. Rising cases of hypertension and other cardiovascular diseases boosts the non-cardioselective beta blockers market. It is used to prevent or improve symptoms in people who've abnormal coronary heart rhythm, Chest ache, coronary heart assaults, coronary heart failure, migraine, and kinds of tremors. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cardioselective beta blockers market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Cardioselective beta blockers intercept the activation of beta-1 adrenergic receptors present at the nerve endings of the sympathetic nervous system. This eventually results in diminished activity of the heart, such as a reduction in systolic pressure, heart rate and cardiac contractility. Cardioselective agents have a better affinity for β1-adrenergic receptors located in the heart, whereas nonselective agents work on β1-adrenergic receptors and β2-adrenergic receptors located in bronchial musculature.
Cardioselective Beta Blockers Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Angina, Hypertension, Heart Failure, Arrhythmias, Others), Target (Beta-1 Receptors, Beta-2 Receptors, Others), Drugs (Betaxolol, Acebutolol, Esmolol, Atenolol, Others), Route of Administration (Oral, parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Ipca Laboratories Ltd (India)
|
|
Market Opportunities
|
|
Global Cardioselective Beta Blockers Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of the population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rising Prevalence of Hypertension
As per the American College of Cardiology, older adults are mostly undertreated for high blood pressure, despite having the maximum prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). According to the National Health and Nutrition Examination Survey (NHANES) records in the U.S., hypertension affects 70% of persons over 65 years. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is projected to rise to 20% by 2050. This will create more opportunities for the market growth as the demand for the blockers also increases.
- Increased Clinical Studies and Government Initiatives
Rising awareness about the beta blockers and studies that are conducted for development in identifying the diseases that by government and private companies for better knowledge of these blockers is likely to drive the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of calcium channel blockers delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who cannot treat the patients with these agents could curb the growth of the global cardioselective beta blockers market over a forecast period.
- Side Effects of Cardioselective Beta Blockers
There are various side effects associated with cardioselective beta blockers such as upset stomach, nausea, diarrhea or constipation, and erectile dysfunction when taking beta-blockers that hamper the market growth.
This global cardioselective beta blockers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cardioselective beta blockers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Cardioselective Beta Blockers Market
The COVID-19 pandemic faced moderately great impact on the market growth. Hypertension is one of the most common phenomenon in COVID-19 patients; thus, beta-blockers are widely used. In addition to this, the pandemic is interrupting the medical supply chain, and the delivery of the prooducts. But in the post pandemic era, the market is rising as the hospitals and clinics are free from the tedious responsibilities of COVID-19 patients.Thus, the market will undergo growth during the forecast period.
Global Cardioselective Beta Blockers Market Scope
The global cardioselective beta blockers market is segmented on the basis of indication, drugs, target, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Angina
- Hypertension
- Heart Failure
- Arrhythmias
- Others
Target
- Beta-1 Receptors
- Beta-2 Receptors
- Others
Drugs
- Betaxolol
- Acebutolol
- Esmolol
- Atenolol
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cardioselective Beta Blockers Market Regional Analysis/Insights
The global cardioselective beta blockers market is analyzed and market size insights and trends are provided by indication, drugs, target, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global cardioselective beta blockers market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global cardioselective beta blockers market throughout the forecasted period due to the increase prevalence of cardiovascular complications and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cardioselective Beta Blockers Market Share Analysis
The global cardioselective beta blockers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cardioselective beta blockers market
Key players operating in the global cardioselective beta blockers market include:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Group (India)
- Pfizer Inc (U.S.)
- Lupin (India)
- GSK Plc (U.K.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- Pierre Fabre Group (France)
SKU-